<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4874">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196988</url>
  </required_header>
  <id_info>
    <org_study_id>113275</org_study_id>
    <nct_id>NCT01196988</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK)
      Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to
      describe safety and immunogenicity of the GSK Biologicals' investigational vaccine
      GSK2321138A in children aged 6 to 35 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</measure>
    <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful (Child &lt;6 years) or pain that prevented normal activity (Child &gt;6 years). Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Younger Than 6 Years Old.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Aged 6 Years or Older.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 28-day (Days 0-27) follow-up period after any vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Medically Attended Adverse Events (MAEs).</measure>
    <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MAEs were defined as AEs that resulted in medical attention (defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason). Any = any MAE regardless of intensity or relationship to vaccination. Grade 3 MAE = MAE which prevented normal, everyday activities. Related = MAE assessed by the investigator as related to the vaccination. Assessment of intensity for MAEs was not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Potential Immune-Mediated Diseases (pIMDs).</measure>
    <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
    <safety_issue>No</safety_issue>
    <description>pIMDs were defined as a subset of AEs that included both clearly autoimmune diseases (AID) and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited local symptoms for duration were pain, redness and swelling at the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited general symptoms for duration were drowsiness, fatigue, gastrointestinal symptoms (Gastro.), headache, irritability, loss of appetite, muscle aches, shivering and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)].</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3027</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2321138A 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2604409A Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2321138A 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK2321138A</intervention_name>
    <description>intramuscular injections</description>
    <arm_group_label>GSK2321138A 1 Group</arm_group_label>
    <arm_group_label>GSK2321138A 2 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluarixTM</intervention_name>
    <description>intramuscular injections</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK2604409A</intervention_name>
    <description>intramuscular injections</description>
    <arm_group_label>GSK2604409A Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LAR) can and will comply with the requirements of the protocol.

          -  For non US countries:

          -  - Children, male or female, aged between 6 months and 17 years at the time of the
             first study vaccination.

        For US :

          -  Children, male or female, aged between 3 and 17 years at the time of the first study
             vaccination

          -  Written informed consent obtained from the subject parent(s) or LAR(s) of the
             subject. Assent obtained from the subject when applicable.

          -  Subjects in stable health as determined by investigator's clinical examination and
             assessment of subjects' medical history.

          -  Written informed assent obtained from the subject if/as required by local
             regulations.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  - has practiced adequate contraception for 30 days prior to vaccination,

          -  - and has a negative urine pregnancy test on the day of vaccination,

          -  - and has agreed to continue adequate contraception during the entire treatment
             period and for 2 months after completion of the vaccination series

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of the study vaccine or planned use during
             the study period. Routine registered childhood vaccinations are permitted.

          -  Planned administration of any vaccine 30 days prior and 30 days after any study
             vaccine administration.

          -  Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by medical history and physical examination.

          -  Prior receipt of any seasonal or pandemic influenza vaccine (registered or
             investigational) within 6 months preceding the first dose of study vaccine, or
             planned use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             three months prior to enrolment in this study or planned administration during the
             study period.

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the enrolment in this study, or planned during the study.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  History of seizures or progressive neurological disease.

          -  History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated
             influenza virus vaccine.

          -  Concurrently participating in another clinical study, at any time during the study
             period in which the subject has been or will be exposed to an investigational or a
             non-investigational product .

          -  History of hypersensitivity to a previous dose of influenza vaccine, history of any
             reaction or hypersensitivity likely to be exacerbated by any component of the
             vaccines

          -  Acute disease and/or fever at the time of enrolment

          -  Ongoing aspirin therapy

          -  Pregnant or lactating female

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Any other condition which, in the opinion of the investigator, prevents the subject
             from participating in the study

          -  Child in Care.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elmira</city>
        <state>New York</state>
        <zip>14901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decin</city>
        <zip>405 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Humpolec</city>
        <zip>396 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolin</city>
        <zip>28002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nachod</city>
        <zip>547 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odolena voda</city>
        <zip>25070</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <zip>1600</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essey les Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Bouexiere</city>
        <zip>35340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seysses</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwaebisch-Hall</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauberbischofsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuttlingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gilching</city>
        <state>Bayern</state>
        <zip>82205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kirchheim</city>
        <state>Bayern</state>
        <zip>85551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81735</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Noerdlingen</city>
        <state>Bayern</state>
        <zip>86720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eschwege</city>
        <state>Hessen</state>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heiligenhaus</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42579</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kleve-Materborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willich</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47877</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weimar</city>
        <state>Thueringen</state>
        <zip>99425</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dasmariñas, Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Philippines</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.</citation>
    <PMID>23470848</PMID>
  </reference>
  <reference>
    <citation>Domachowske J et al. Immunogenicity and safety profile of a candidate inactivated quadrivalent influenza vaccine in children: a randomized controlled study. Abstract presented at the 4th International Conference, Influenza Vaccines for the World (IVW), Algarve, Portugal, 9-12 October 2012.</citation>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>March 23, 2015</lastchanged_date>
  <firstreceived_date>September 7, 2010</firstreceived_date>
  <firstreceived_results_date>December 17, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK Biologicals influenza vaccine GSK2321138A</keyword>
  <keyword>influenza infection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were differentiated according to their priming status. Primed subjects had received at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine and had received 2 doses of seasonal influenza in the last season or had received at least 1 dose prior to last season. Unprimed subjects had not.</recruitment_details>
      <pre_assignment_details>3015 subjects out of the 3027 who were enrolled in the study were vaccinated. Remaining subjects were not included in the participant flow as started as they failed to meet protocol criteria. The treatment was stratified by age strata: 3-8 and 9-17 years. Another arm evaluates the GSK2321138A vaccine for children aged 6-17 and 18-35 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2321138A 1 Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="P3">
          <title>GSK2604409A Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="P4">
          <title>GSK2321138A 2 Group</title>
          <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="915"/>
                <participants group_id="P2" count="912"/>
                <participants group_id="P3" count="911"/>
                <participants group_id="P4" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="891"/>
                <participants group_id="P2" count="880"/>
                <participants group_id="P3" count="886"/>
                <participants group_id="P4" count="276"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2321138A 1 Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="B3">
          <title>GSK2604409A Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="B4">
          <title>GSK2321138A 2 Group</title>
          <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="915"/>
                <measurement group_id="B2" value="912"/>
                <measurement group_id="B3" value="911"/>
                <measurement group_id="B4" value="277"/>
                <measurement group_id="B5" value="3015"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="98.5" spread="44.40"/>
                <measurement group_id="B2" value="98.2" spread="45.50"/>
                <measurement group_id="B3" value="99.6" spread="44.20"/>
                <measurement group_id="B4" value="22.1" spread="8.02"/>
                <measurement group_id="B5" value="79.6" spread="35.53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="443"/>
                <measurement group_id="B2" value="439"/>
                <measurement group_id="B3" value="440"/>
                <measurement group_id="B4" value="118"/>
                <measurement group_id="B5" value="1440"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="472"/>
                <measurement group_id="B2" value="473"/>
                <measurement group_id="B3" value="471"/>
                <measurement group_id="B4" value="159"/>
                <measurement group_id="B5" value="1575"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                  <measurement group_id="O4" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
            <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.6" lower_limit="19.7" upper_limit="23.7"/>
                  <measurement group_id="O2" value="24.9" lower_limit="22.8" upper_limit="27.3"/>
                  <measurement group_id="O3" value="22.1" lower_limit="20.1" upper_limit="24.2"/>
                  <measurement group_id="O4" value="12.3" lower_limit="10.2" upper_limit="14.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="386.2" lower_limit="357.3" upper_limit="417.4"/>
                  <measurement group_id="O2" value="433.2" lower_limit="401.0" upper_limit="468.0"/>
                  <measurement group_id="O3" value="422.3" lower_limit="390.5" upper_limit="456.5"/>
                  <measurement group_id="O4" value="140.0" lower_limit="113.7" upper_limit="172.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" lower_limit="26.6" upper_limit="31.6"/>
                  <measurement group_id="O2" value="31.4" lower_limit="28.8" upper_limit="34.2"/>
                  <measurement group_id="O3" value="31.2" lower_limit="28.6" upper_limit="34.2"/>
                  <measurement group_id="O4" value="8.6" lower_limit="7.4" upper_limit="9.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="228.8" lower_limit="215.0" upper_limit="243.4"/>
                  <measurement group_id="O2" value="227.3" lower_limit="213.3" upper_limit="242.3"/>
                  <measurement group_id="O3" value="234.0" lower_limit="219.1" upper_limit="249.9"/>
                  <measurement group_id="O4" value="87.5" lower_limit="73.8" upper_limit="103.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.9" lower_limit="28.2" upper_limit="33.9"/>
                  <measurement group_id="O2" value="31.0" lower_limit="28.2" upper_limit="34.0"/>
                  <measurement group_id="O3" value="33.2" lower_limit="30.2" upper_limit="36.6"/>
                  <measurement group_id="O4" value="9.0" lower_limit="7.9" upper_limit="10.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="244.2" lower_limit="227.5" upper_limit="262.1"/>
                  <measurement group_id="O2" value="245.6" lower_limit="229.2" upper_limit="263.2"/>
                  <measurement group_id="O3" value="88.4" lower_limit="81.5" upper_limit="95.8"/>
                  <measurement group_id="O4" value="86.4" lower_limit="72.6" upper_limit="102.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77.3" lower_limit="70.0" upper_limit="85.3"/>
                  <measurement group_id="O2" value="77.2" lower_limit="70.0" upper_limit="85.2"/>
                  <measurement group_id="O3" value="84.7" lower_limit="76.6" upper_limit="93.6"/>
                  <measurement group_id="O4" value="13.1" lower_limit="11.4" upper_limit="15.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="569.6" lower_limit="533.6" upper_limit="608.1"/>
                  <measurement group_id="O2" value="224.7" lower_limit="207.9" upper_limit="242.9"/>
                  <measurement group_id="O3" value="643.3" lower_limit="603.2" upper_limit="686.1"/>
                  <measurement group_id="O4" value="167.7" lower_limit="144.1" upper_limit="195.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="790"/>
                  <measurement group_id="O2" value="818"/>
                  <measurement group_id="O3" value="800"/>
                  <measurement group_id="O4" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease.</title>
            <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="722"/>
                  <measurement group_id="O2" value="735"/>
                  <measurement group_id="O3" value="733"/>
                  <measurement group_id="O4" value="181"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="571"/>
                  <measurement group_id="O2" value="578"/>
                  <measurement group_id="O3" value="575"/>
                  <measurement group_id="O4" value="159"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="553"/>
                  <measurement group_id="O2" value="560"/>
                  <measurement group_id="O3" value="237"/>
                  <measurement group_id="O4" value="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="573"/>
                  <measurement group_id="O2" value="303"/>
                  <measurement group_id="O3" value="566"/>
                  <measurement group_id="O4" value="191"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.7" lower_limit="18.3" upper_limit="23.3"/>
                  <measurement group_id="O2" value="22.2" lower_limit="19.8" upper_limit="24.9"/>
                  <measurement group_id="O3" value="22.4" lower_limit="19.8" upper_limit="25.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="353.4" lower_limit="319.9" upper_limit="390.3"/>
                  <measurement group_id="O2" value="382.1" lower_limit="345.4" upper_limit="422.7"/>
                  <measurement group_id="O3" value="381.3" lower_limit="345.0" upper_limit="421.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.2" lower_limit="20.2" upper_limit="26.6"/>
                  <measurement group_id="O2" value="30.2" lower_limit="26.1" upper_limit="34.9"/>
                  <measurement group_id="O3" value="21.5" lower_limit="18.6" upper_limit="24.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="445.8" lower_limit="393.9" upper_limit="504.7"/>
                  <measurement group_id="O2" value="533.3" lower_limit="474.9" upper_limit="599.0"/>
                  <measurement group_id="O3" value="502.0" lower_limit="444.1" upper_limit="567.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.3" lower_limit="26.1" upper_limit="32.9"/>
                  <measurement group_id="O2" value="32.9" lower_limit="29.2" upper_limit="37.0"/>
                  <measurement group_id="O3" value="31.5" lower_limit="28.0" upper_limit="35.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="245.5" lower_limit="226.4" upper_limit="266.2"/>
                  <measurement group_id="O2" value="242.0" lower_limit="222.9" upper_limit="262.8"/>
                  <measurement group_id="O3" value="244.4" lower_limit="224.1" upper_limit="266.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.5" lower_limit="25.1" upper_limit="32.3"/>
                  <measurement group_id="O2" value="29.0" lower_limit="25.8" upper_limit="32.7"/>
                  <measurement group_id="O3" value="30.8" lower_limit="27.0" upper_limit="35.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204.1" lower_limit="185.5" upper_limit="224.5"/>
                  <measurement group_id="O2" value="204.9" lower_limit="185.4" upper_limit="226.6"/>
                  <measurement group_id="O3" value="217.5" lower_limit="196.9" upper_limit="240.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.1" lower_limit="24.0" upper_limit="30.6"/>
                  <measurement group_id="O2" value="25.1" lower_limit="22.3" upper_limit="28.3"/>
                  <measurement group_id="O3" value="27.9" lower_limit="24.6" upper_limit="31.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="236.3" lower_limit="215.4" upper_limit="259.2"/>
                  <measurement group_id="O2" value="222.3" lower_limit="202.8" upper_limit="243.7"/>
                  <measurement group_id="O3" value="79.2" lower_limit="71.2" upper_limit="88.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.3" lower_limit="33.4" upper_limit="43.9"/>
                  <measurement group_id="O2" value="43.9" lower_limit="38.2" upper_limit="50.6"/>
                  <measurement group_id="O3" value="44.7" lower_limit="38.6" upper_limit="51.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="257.5" lower_limit="230.7" upper_limit="287.5"/>
                  <measurement group_id="O2" value="289.8" lower_limit="262.1" upper_limit="320.4"/>
                  <measurement group_id="O3" value="106.4" lower_limit="94.6" upper_limit="119.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.9" lower_limit="48.7" upper_limit="61.9"/>
                  <measurement group_id="O2" value="51.9" lower_limit="45.9" upper_limit="58.7"/>
                  <measurement group_id="O3" value="57.6" lower_limit="50.9" upper_limit="65.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="481.3" lower_limit="443.2" upper_limit="522.8"/>
                  <measurement group_id="O2" value="163.5" lower_limit="148.4" upper_limit="180.1"/>
                  <measurement group_id="O3" value="566.7" lower_limit="522.9" upper_limit="614.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134.3" lower_limit="115.2" upper_limit="156.5"/>
                  <measurement group_id="O2" value="149.3" lower_limit="130.3" upper_limit="171.1"/>
                  <measurement group_id="O3" value="162.8" lower_limit="140.4" upper_limit="188.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="748.1" lower_limit="676.9" upper_limit="826.8"/>
                  <measurement group_id="O2" value="380.6" lower_limit="342.1" upper_limit="423.4"/>
                  <measurement group_id="O3" value="797.9" lower_limit="719.5" upper_limit="885.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).
Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
            <units>titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.1" lower_limit="5.5" upper_limit="9.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.2" lower_limit="39.9" upper_limit="79.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.6" lower_limit="12.3" upper_limit="19.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="208.3" lower_limit="164.6" upper_limit="263.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.2" lower_limit="5.1" upper_limit="7.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.8" lower_limit="33.7" upper_limit="57.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.8" lower_limit="8.1" upper_limit="11.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="118.2" lower_limit="96.8" upper_limit="144.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.9" lower_limit="5.3" upper_limit="6.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40.2" lower_limit="31.2" upper_limit="51.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.8" lower_limit="9.0" upper_limit="13.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120.7" lower_limit="98.2" upper_limit="148.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.0" lower_limit="7.9" upper_limit="12.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.5" lower_limit="73.5" upper_limit="119.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.8" lower_limit="12.4" upper_limit="17.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="216.3" lower_limit="180.9" upper_limit="258.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="790"/>
                  <measurement group_id="O2" value="818"/>
                  <measurement group_id="O3" value="800"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="447"/>
                  <measurement group_id="O2" value="468"/>
                  <measurement group_id="O3" value="457"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="275"/>
                  <measurement group_id="O2" value="267"/>
                  <measurement group_id="O3" value="276"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="367"/>
                  <measurement group_id="O2" value="365"/>
                  <measurement group_id="O3" value="376"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="204"/>
                  <measurement group_id="O2" value="213"/>
                  <measurement group_id="O3" value="199"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="364"/>
                  <measurement group_id="O2" value="367"/>
                  <measurement group_id="O3" value="154"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="189"/>
                  <measurement group_id="O2" value="193"/>
                  <measurement group_id="O3" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="376"/>
                  <measurement group_id="O2" value="203"/>
                  <measurement group_id="O3" value="403"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="197"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                  <measurement group_id="O4" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="404"/>
                  <measurement group_id="O3" value="353"/>
                  <measurement group_id="O4" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="764"/>
                  <measurement group_id="O2" value="793"/>
                  <measurement group_id="O3" value="778"/>
                  <measurement group_id="O4" value="187"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="412"/>
                  <measurement group_id="O3" value="409"/>
                  <measurement group_id="O4" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="775"/>
                  <measurement group_id="O2" value="800"/>
                  <measurement group_id="O3" value="773"/>
                  <measurement group_id="O4" value="169"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="381"/>
                  <measurement group_id="O2" value="396"/>
                  <measurement group_id="O3" value="399"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="770"/>
                  <measurement group_id="O2" value="790"/>
                  <measurement group_id="O3" value="639"/>
                  <measurement group_id="O4" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="565"/>
                  <measurement group_id="O2" value="575"/>
                  <measurement group_id="O3" value="593"/>
                  <measurement group_id="O4" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="785"/>
                  <measurement group_id="O2" value="772"/>
                  <measurement group_id="O3" value="798"/>
                  <measurement group_id="O4" value="212"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="206"/>
                  <measurement group_id="O2" value="234"/>
                  <measurement group_id="O3" value="230"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="469"/>
                  <measurement group_id="O2" value="491"/>
                  <measurement group_id="O3" value="487"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="170"/>
                  <measurement group_id="O3" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="295"/>
                  <measurement group_id="O2" value="302"/>
                  <measurement group_id="O3" value="291"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="253"/>
                  <measurement group_id="O2" value="277"/>
                  <measurement group_id="O3" value="269"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="477"/>
                  <measurement group_id="O2" value="496"/>
                  <measurement group_id="O3" value="481"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="135"/>
                  <measurement group_id="O3" value="140"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="298"/>
                  <measurement group_id="O2" value="304"/>
                  <measurement group_id="O3" value="292"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="218"/>
                  <measurement group_id="O3" value="232"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="478"/>
                  <measurement group_id="O2" value="489"/>
                  <measurement group_id="O3" value="378"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="178"/>
                  <measurement group_id="O3" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="292"/>
                  <measurement group_id="O2" value="301"/>
                  <measurement group_id="O3" value="261"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="315"/>
                  <measurement group_id="O2" value="309"/>
                  <measurement group_id="O3" value="329"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="485"/>
                  <measurement group_id="O2" value="465"/>
                  <measurement group_id="O3" value="503"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="250"/>
                  <measurement group_id="O2" value="266"/>
                  <measurement group_id="O3" value="264"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="300"/>
                  <measurement group_id="O2" value="307"/>
                  <measurement group_id="O3" value="295"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                  <measurement group_id="O4" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="218"/>
                  <measurement group_id="O3" value="202"/>
                  <measurement group_id="O4" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="732"/>
                  <measurement group_id="O2" value="763"/>
                  <measurement group_id="O3" value="744"/>
                  <measurement group_id="O4" value="155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="228"/>
                  <measurement group_id="O2" value="245"/>
                  <measurement group_id="O3" value="267"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="721"/>
                  <measurement group_id="O2" value="748"/>
                  <measurement group_id="O3" value="721"/>
                  <measurement group_id="O4" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="244"/>
                  <measurement group_id="O2" value="258"/>
                  <measurement group_id="O3" value="269"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="708"/>
                  <measurement group_id="O2" value="733"/>
                  <measurement group_id="O3" value="488"/>
                  <measurement group_id="O4" value="140"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="454"/>
                  <measurement group_id="O2" value="462"/>
                  <measurement group_id="O3" value="476"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="779"/>
                  <measurement group_id="O2" value="692"/>
                  <measurement group_id="O3" value="784"/>
                  <measurement group_id="O4" value="175"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="128"/>
                  <measurement group_id="O3" value="141"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="453"/>
                  <measurement group_id="O2" value="471"/>
                  <measurement group_id="O3" value="464"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="90"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="279"/>
                  <measurement group_id="O2" value="292"/>
                  <measurement group_id="O3" value="280"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 3-8 years [N=488; 511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="177"/>
                  <measurement group_id="O3" value="190"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 3-8 years [N=489; 510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="446"/>
                  <measurement group_id="O2" value="462"/>
                  <measurement group_id="O3" value="446"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="275"/>
                  <measurement group_id="O2" value="286"/>
                  <measurement group_id="O3" value="275"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="430"/>
                  <measurement group_id="O2" value="441"/>
                  <measurement group_id="O3" value="286"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="118"/>
                  <measurement group_id="O3" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="278"/>
                  <measurement group_id="O2" value="292"/>
                  <measurement group_id="O3" value="202"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="233"/>
                  <measurement group_id="O2" value="227"/>
                  <measurement group_id="O3" value="248"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="480"/>
                  <measurement group_id="O2" value="395"/>
                  <measurement group_id="O3" value="493"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                  <measurement group_id="O2" value="235"/>
                  <measurement group_id="O3" value="228"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="299"/>
                  <measurement group_id="O2" value="297"/>
                  <measurement group_id="O3" value="291"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:80. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6-17 months and 18-35 months.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="132"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                  <measurement group_id="O4" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="92"/>
                  <measurement group_id="O3" value="79"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="669"/>
                  <measurement group_id="O2" value="720"/>
                  <measurement group_id="O3" value="690"/>
                  <measurement group_id="O4" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="124"/>
                  <measurement group_id="O3" value="121"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="597"/>
                  <measurement group_id="O2" value="597"/>
                  <measurement group_id="O3" value="599"/>
                  <measurement group_id="O4" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="126"/>
                  <measurement group_id="O3" value="148"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="578"/>
                  <measurement group_id="O2" value="607"/>
                  <measurement group_id="O3" value="300"/>
                  <measurement group_id="O4" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE [N=790;819;800;232]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="300"/>
                  <measurement group_id="O2" value="324"/>
                  <measurement group_id="O3" value="327"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST [N=791;818;801;234]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="730"/>
                  <measurement group_id="O2" value="564"/>
                  <measurement group_id="O3" value="756"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="791"/>
                  <measurement group_id="O2" value="819"/>
                  <measurement group_id="O3" value="801"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="410"/>
                  <measurement group_id="O2" value="442"/>
                  <measurement group_id="O3" value="428"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Cal/7/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="259"/>
                  <measurement group_id="O2" value="278"/>
                  <measurement group_id="O3" value="262"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="92"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="380"/>
                  <measurement group_id="O2" value="385"/>
                  <measurement group_id="O3" value="390"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Vic/210/09, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="212"/>
                  <measurement group_id="O3" value="209"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="66"/>
                  <measurement group_id="O3" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="349"/>
                  <measurement group_id="O2" value="357"/>
                  <measurement group_id="O3" value="174"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/60/08, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="229"/>
                  <measurement group_id="O2" value="250"/>
                  <measurement group_id="O3" value="126"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 3-8 years [N=488;511;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="155"/>
                  <measurement group_id="O3" value="150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 3-8 years [N=489;510;504]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="444"/>
                  <measurement group_id="O2" value="301"/>
                  <measurement group_id="O3" value="473"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, PRE, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="165"/>
                  <measurement group_id="O2" value="169"/>
                  <measurement group_id="O3" value="177"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Bri/3/07, POST, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="286"/>
                  <measurement group_id="O2" value="263"/>
                  <measurement group_id="O3" value="283"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>A seroprotected subject was defined as as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
        <time_frame>At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="234"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>A seroprotected subject was defined as as a vaccinated subject who had a serum HI titer ≥ 1:120. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST, 6-17 months [N=71]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, PRE, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, POST, 18-35 months [N=163]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
        <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="790"/>
                  <measurement group_id="O2" value="818"/>
                  <measurement group_id="O3" value="800"/>
                  <measurement group_id="O4" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
            <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata).</description>
            <units>fold increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.0" lower_limit="16.6" upper_limit="19.5"/>
                  <measurement group_id="O2" value="17.4" lower_limit="16.0" upper_limit="18.8"/>
                  <measurement group_id="O3" value="19.2" lower_limit="17.7" upper_limit="20.9"/>
                  <measurement group_id="O4" value="11.7" lower_limit="10.2" upper_limit="13.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.9" lower_limit="7.3" upper_limit="8.6"/>
                  <measurement group_id="O2" value="7.2" lower_limit="6.7" upper_limit="7.8"/>
                  <measurement group_id="O3" value="7.5" lower_limit="6.9" upper_limit="8.1"/>
                  <measurement group_id="O4" value="10.4" lower_limit="9.0" upper_limit="11.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.9" lower_limit="7.3" upper_limit="8.6"/>
                  <measurement group_id="O2" value="7.9" lower_limit="7.2" upper_limit="8.6"/>
                  <measurement group_id="O3" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                  <measurement group_id="O4" value="9.7" lower_limit="8.5" upper_limit="11.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.4" lower_limit="6.8" upper_limit="8.0"/>
                  <measurement group_id="O2" value="2.9" lower_limit="2.7" upper_limit="3.1"/>
                  <measurement group_id="O3" value="7.6" lower_limit="7.0" upper_limit="8.3"/>
                  <measurement group_id="O4" value="12.9" lower_limit="11.0" upper_limit="15.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="790"/>
                  <measurement group_id="O2" value="818"/>
                  <measurement group_id="O3" value="800"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 3-8 years and 9-17 years.</description>
            <units>fold increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.2" lower_limit="15.6" upper_limit="19.0"/>
                  <measurement group_id="O2" value="17.2" lower_limit="15.6" upper_limit="18.9"/>
                  <measurement group_id="O3" value="17.2" lower_limit="15.6" upper_limit="18.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.2" lower_limit="16.7" upper_limit="22.2"/>
                  <measurement group_id="O2" value="17.7" lower_limit="15.2" upper_limit="20.5"/>
                  <measurement group_id="O3" value="23.3" lower_limit="20.3" upper_limit="26.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.4" lower_limit="7.6" upper_limit="9.3"/>
                  <measurement group_id="O2" value="7.3" lower_limit="6.6" upper_limit="8.1"/>
                  <measurement group_id="O3" value="7.8" lower_limit="7.1" upper_limit="8.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2" lower_limit="6.2" upper_limit="8.2"/>
                  <measurement group_id="O2" value="7.1" lower_limit="6.2" upper_limit="8.1"/>
                  <measurement group_id="O3" value="7.1" lower_limit="6.2" upper_limit="8.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.8" lower_limit="7.9" upper_limit="9.8"/>
                  <measurement group_id="O2" value="8.8" lower_limit="7.9" upper_limit="9.8"/>
                  <measurement group_id="O3" value="2.8" lower_limit="2.6" upper_limit="3.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.7" lower_limit="5.8" upper_limit="7.8"/>
                  <measurement group_id="O2" value="6.6" lower_limit="5.7" upper_limit="7.6"/>
                  <measurement group_id="O3" value="2.4" lower_limit="2.1" upper_limit="2.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 3-8 years [N=488;510;503]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.8" lower_limit="7.9" upper_limit="9.8"/>
                  <measurement group_id="O2" value="3.1" lower_limit="2.9" upper_limit="3.4"/>
                  <measurement group_id="O3" value="9.9" lower_limit="8.9" upper_limit="11.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 9-17 years [N=302;308;297]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.6" lower_limit="4.9" upper_limit="6.3"/>
                  <measurement group_id="O2" value="2.5" lower_limit="2.3" upper_limit="2.8"/>
                  <measurement group_id="O3" value="4.9" lower_limit="4.3" upper_limit="5.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
        <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
        <time_frame>At Day 28 (for primed subjects) and Day 56 (for unprimed subjects)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Geometric Increase (MGI) Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata.</title>
            <description>MGI is defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer. The 4 influenza strains assessed were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (Victoria) and FLU B/Brisbane/3/07 (Yamagata). Subjects were assessed according to 2 age strata: 6 -17 months and 18-35 months.</description>
            <units>fold increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FLU A/California/7/09, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.2" lower_limit="6.4" upper_limit="10.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/California/7/09, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.7" lower_limit="11.7" upper_limit="16.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.3" lower_limit="5.9" upper_limit="9.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU A/Victoria/210/09, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.1" lower_limit="10.2" upper_limit="14.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.9" lower_limit="5.4" upper_limit="8.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/60/08, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.3" lower_limit="9.6" upper_limit="13.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 6-17 months [N=70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.5" lower_limit="7.0" upper_limit="12.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>FLU B/Brisbane/3/07, 18-35 months [N=162]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.8" lower_limit="12.2" upper_limit="18.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful (Child &lt;6 years) or pain that prevented normal activity (Child &gt;6 years). Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of the injection site.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results and with the symptom completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="903"/>
                  <measurement group_id="O2" value="902"/>
                  <measurement group_id="O3" value="906"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
            <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful (Child &lt;6 years) or pain that prevented normal activity (Child &gt;6 years). Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of the injection site.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="444"/>
                  <measurement group_id="O2" value="425"/>
                  <measurement group_id="O3" value="416"/>
                  <measurement group_id="O4" value="116"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225"/>
                  <measurement group_id="O2" value="214"/>
                  <measurement group_id="O3" value="206"/>
                  <measurement group_id="O4" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="196"/>
                  <measurement group_id="O2" value="193"/>
                  <measurement group_id="O3" value="160"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Younger Than 6 Years Old.</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="291"/>
                  <measurement group_id="O2" value="314"/>
                  <measurement group_id="O3" value="280"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Younger Than 6 Years Old.</title>
            <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="59"/>
                  <measurement group_id="O4" value="84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature ≥37.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="51"/>
                  <measurement group_id="O3" value="41"/>
                  <measurement group_id="O4" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature &gt;39°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Aged 6 Years or Older.</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after any vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="613"/>
                  <measurement group_id="O2" value="589"/>
                  <measurement group_id="O3" value="626"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Aged 6 Years or Older.</title>
            <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = temperature &gt;39.0°C.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="118"/>
                  <measurement group_id="O3" value="114"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="81"/>
                  <measurement group_id="O3" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Gastro.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Gastro.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Gastro.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="125"/>
                  <measurement group_id="O3" value="114"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="75"/>
                  <measurement group_id="O3" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Joint Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Joint Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Joint Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="116"/>
                  <measurement group_id="O2" value="106"/>
                  <measurement group_id="O3" value="106"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="81"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature ≥37.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature &gt;39°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Temperature</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 28-day (Days 0-27) follow-up period after any vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="915"/>
                  <measurement group_id="O2" value="912"/>
                  <measurement group_id="O3" value="911"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="284"/>
                  <measurement group_id="O2" value="305"/>
                  <measurement group_id="O3" value="308"/>
                  <measurement group_id="O4" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with grade 3 AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Medically Attended Adverse Events (MAEs).</title>
        <description>MAEs were defined as AEs that resulted in medical attention (defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason). Any = any MAE regardless of intensity or relationship to vaccination. Grade 3 MAE = MAE which prevented normal, everyday activities. Related = MAE assessed by the investigator as related to the vaccination. Assessment of intensity for MAEs was not performed.</description>
        <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="915"/>
                  <measurement group_id="O2" value="912"/>
                  <measurement group_id="O3" value="911"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Medically Attended Adverse Events (MAEs).</title>
            <description>MAEs were defined as AEs that resulted in medical attention (defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason). Any = any MAE regardless of intensity or relationship to vaccination. Grade 3 MAE = MAE which prevented normal, everyday activities. Related = MAE assessed by the investigator as related to the vaccination. Assessment of intensity for MAEs was not performed.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="271"/>
                  <measurement group_id="O2" value="278"/>
                  <measurement group_id="O3" value="303"/>
                  <measurement group_id="O4" value="171"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with Grade 3 MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Analysis was not performed.</measurement>
                  <measurement group_id="O2" value="NA">Analysis was not performed.</measurement>
                  <measurement group_id="O3" value="NA">Analysis was not performed.</measurement>
                  <measurement group_id="O4" value="NA">Analysis was not performed.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Potential Immune-Mediated Diseases (pIMDs).</title>
        <description>pIMDs were defined as a subset of AEs that included both clearly autoimmune diseases (AID) and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
        <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="915"/>
                  <measurement group_id="O2" value="912"/>
                  <measurement group_id="O3" value="911"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any and Related Potential Immune-Mediated Diseases (pIMDs).</title>
            <description>pIMDs were defined as a subset of AEs that included both clearly autoimmune diseases (AID) and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any pIMD(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related pIMD(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the entire study period (Day 0 - Day 180)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="915"/>
                  <measurement group_id="O2" value="912"/>
                  <measurement group_id="O3" value="911"/>
                  <measurement group_id="O4" value="277"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Subjects with any SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subjects with related SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited Local Symptoms.</title>
        <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited local symptoms for duration were pain, redness and swelling at the injection site.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="395"/>
                  <measurement group_id="O2" value="382"/>
                  <measurement group_id="O3" value="365"/>
                  <measurement group_id="O4" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Days With Solicited Local Symptoms.</title>
            <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited local symptoms for duration were pain, redness and swelling at the injection site.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Pain, Dose 1 [N=395;382;365;94]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain, Dose 2 [N=175;156;160;70]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness, Dose 1 [N=208;192;189;84]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.5" upper_limit="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness, Dose 2 [N=75;80;76;69]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling, Dose 1 [N=167;155;135;44]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling, Dose 2 [N=70;65;59;39]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited General Symptoms</title>
        <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited general symptoms for duration were drowsiness, fatigue, gastrointestinal symptoms (Gastro.), headache, irritability, loss of appetite, muscle aches, shivering and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)].</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort, on vaccinated subjects with available results and with the symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A 1 Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GSK2321138A 2 Group</title>
            <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                  <measurement group_id="O2" value="113"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Days With Solicited General Symptoms</title>
            <description>The number of days with any grade of local symptoms after Dose 1 and Dose 2 vaccination respectively was tabulated. Assessed solicited general symptoms for duration were drowsiness, fatigue, gastrointestinal symptoms (Gastro.), headache, irritability, loss of appetite, muscle aches, shivering and temperature [axillary temperature equal to or above 37.5 degrees Celsius (°C)].</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>Drowsiness, Dose 1 [N=50;39;38;66]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Drowsiness, Dose 2 [N=29;29;32;45]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue, Dose 1 [N=121;109;97;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue, Dose 2 [N=33;25;33,0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastro., Dose 1 [N=60;56;45;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastro., Dose 2 [N=11;9;8;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache, Dose 1 [N=100;113;95;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.5"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache, Dose 2 [N=19;21;29;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability, Dose 1 [N=49;42;40;79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability, Dose 2 [N=37;33;27;79]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint pain, Dose 1 [N=60;55;46;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint pain, Dose 2 [N=18;14;10;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite, Dose 1 [N=45;29;25;56]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  <measurement group_id="O4" value="3.0" lower_limit="1.0" upper_limit="4.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite, Dose 2 [N=22;26;26;50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches, Dose 1 [N=107;94;99;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches, Dose 2 [N=25;20;19;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering, Dose 1 [N=39;26;31;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering, Dose 2 [N=7;6;7;0]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O4" value="NA">Symptom not assessed in this group.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature, Dose 1 [N=63;78;61;45]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temperature, Dose 2 [N=40;44;33;53]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE(s): during the entire study period (Day 0 - Day 180); Solicited local and general symptoms: during the 7-day (Days 0-6) follow-up period after any vaccination, Unsolicited AE(s): during the 28-day follow-up period (Days 0 to 27) after any vaccination.</time_frame>
      <desc>No reported SAE was assessed as related to study vaccination. For systematically assessed other AEs, the number of participants at risk included those from Total Vaccinated cohort with symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2321138A 1 Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="E3">
          <title>GSK2604409A Group</title>
          <description>Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
        <group group_id="E4">
          <title>GSK2321138A 2 Group</title>
          <description>Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="444" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="425" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="416" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Temperature (Axillary)</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>This result is for subjects younger than 6 years old</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="119" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>This result is for subjects younger than 6 years old</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>This result is for subjects younger than 6 years old</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="444" subjects_at_risk="903"/>
                <counts group_id="E2" subjects_affected="425" subjects_at_risk="902"/>
                <counts group_id="E3" subjects_affected="416" subjects_at_risk="906"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="903"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="902"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="906"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="903"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="902"/>
                <counts group_id="E3" subjects_affected="160" subjects_at_risk="906"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Temperature (Axillary)</sub_title>
                <description>This result is for subjects younger than 6 years old</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <description>This result is for subjects 6 years old or older</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="613"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="589"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="915"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="912"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="911"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
